Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/180392
Title: Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19
Author: Buxeda, Anna
Arias Cabrales, Carlos
Pérez Sáez, María José
Cacho, Judit
Cabello Pelegrin, Sheila
Melilli, Edoardo
Aladrén, María José
Galeano, Cristina
Lorenzo, Inmaculada
Mazuecos, Auxiliadora
Saura, Isabel María
Franco, Antonio
Ruiz Fuentes, María Del Carmen
Sánchez Cámara, Luis Alberto
Siverio, Orlando
Martin, María Luisa
González García, Elena
López, Verónica
Martin Moreno, Paloma Leticia
Moina, Iñigo
Moral Berrio, Esperanza
Moreso, Francesc
Portolés, José María
Santana Estupiñán, Raquel
Zárraga, Sofía
Canal, Cristina
Sánchez Álvarez, Emilio
Pascual, Julio (Pascual Santos)
Crespo, Marta
Keywords: SARS-CoV-2
Trasplantament renal
SARS-CoV-2
Kidney transplantation
Issue Date: 1-Sep-2021
Publisher: Elsevier BV
Abstract: Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.ekir.2021.06.023
It is part of: Kidney International Reports, 2021, vol. 6, num. 9, p. 2305-2315
URI: http://hdl.handle.net/2445/180392
Related resource: https://doi.org/10.1016/j.ekir.2021.06.023
ISSN: 2468-0249
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PIIS2468024921012791.pdf703.64 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons